Endocrinology
19 articles on Endocrinology, written by Shotlee and medically reviewed for clinical accuracy.
GLP-1s, Hormones, and Weight Loss: What Women Need to Know
Many women starting GLP-1 therapies experience significant weight loss, only to find their menopausal symptoms—like hot flashes and sleep issues—intensify. This phenomenon is often overlooked because rapid fat loss directly interacts with the body's declining estrogen production, creating a complex hormonal shift that many prescribers are not trained to address.
6 min read
Retatrutide's Triumph: Lilly's Triple Agonist Redefines Weight Loss Potential
Eli Lilly's retatrutide is making waves in the weight loss landscape. This comprehensive look delves into its Phase III results, comparing it to existing treatments and exploring its potential impact on obesity management.
6 min read
GLP-1 Drugs and Vision Loss: Understanding NAION Lawsuits
Recent lawsuits are raising serious questions about the potential for GLP-1 medications, widely used for diabetes and weight loss, to cause a rare but devastating eye condition known as NAION, leading to permanent vision loss. This article delves into the allegations, scientific evidence, and ongoing legal proceedings.
6 min read
GLP-1 Agonists: A New Frontier in Liver Disease Treatment
GLP-1 receptor agonists, renowned for their impact on type 2 diabetes and obesity, are now emerging as powerful allies in the fight against liver diseases like MASH and alcohol-associated liver disease. Discover how these groundbreaking medications are reshaping hepatology.
6 min read
GLP-1s, Liver Health, and Digestive Innovations: A Medical Update
This comprehensive update delves into groundbreaking research on GLP-1 receptor agonists and their impact on liver health, alongside crucial developments in inflammatory bowel disease (IBD) management and innovative approaches to digestive symptom relief. Discover how cutting-edge science is shaping patient care and explore practical implications for managing chronic conditions.
7 min read
Oral GLP-1s for Weight Loss Maintenance: A New Frontier
A groundbreaking study reveals that switching to an oral GLP-1 medication like orforglipron can help individuals maintain a significant portion of their weight loss achieved with injectable therapies, offering a new avenue for long-term obesity management.
6 min read
PCOS Renamed PMOS: A New Era for Endocrine Health
Polycystic Ovary Syndrome (PCOS), a condition affecting millions of women, is undergoing a significant renaming to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change aims to better reflect the condition's complex interplay with endocrine and metabolic systems, potentially improving diagnosis and treatment.
8 min read
GLP-1 Pills for Weight Loss: 8 Key Insights Before You Begin
GLP-1 medications are now available as pills for weight loss, offering a needle-free alternative. This comprehensive guide explores what you need to know before starting, including efficacy, absorption, side effects, and lifestyle considerations.
12 min read
GLP-1 Agonists: Age Limits & Serious Risks of Weight Loss Drugs
This comprehensive guide delves into the critical considerations surrounding GLP-1 agonists for weight loss, addressing common concerns about age limits, potential risks, and practical advice for patients.
7 min read
Oral Semaglutide Shows Promise for Pediatric Type 2 Diabetes
Novo Nordisk recently unveiled compelling topline results from the PIONEER TEENS trial, suggesting that oral semaglutide could become the first oral GLP-1 Receptor Agonist (RA) therapy approved for children and adolescents managing Type 2 Diabetes (T2D). This development addresses a significant gap in pediatric endocrinology, offering a potentially more accessible treatment option.
6 min read
Eli Lilly's Oral GLP-1: A Strong Start Amidst Weight Loss Drug Hype
Eli Lilly's groundbreaking oral GLP-1, Foundayo, is demonstrating a promising launch, exceeding initial expectations and hinting at a significant expansion of the weight loss and diabetes management market. Discover the latest insights and what it means for patients and the industry.
7 min read
GLP-1 Medications: Miracle Drug, Wellness Trend, or Vanity?
GLP-1 medications have surged from diabetes treatment to mainstream wellness. This article examines their medical benefits, potential downsides, and the evolving societal perception of weight loss.
7 min read
GLP-1 Receptor Agonists and Next-Generation Metabolic Hormone Therapies for Chronic Kidney Disease
Clinical trials across the cardiovascular-kidney-metabolic spectrum demonstrate kidney protective effects of incretin-based therapies. Multiple studies show GLP-1RAs and dual GIP/GLP-1RAs reduce kidney disease progression, albuminuria, and kidney failure risk in patients with type 2 diabetes and chronic kidney disease.
10 min read
Pre-GLP-1 Injections: Crucial Exams Physicians Recommend
GLP-1 injectable treatments have surged in popularity in India, prompting medical professionals to emphasize comprehensive diagnostic evaluations before initiating therapy. Key assessments cover metabolic health, organ function, and specific risks to guarantee patient safety. This approach underscores the importance of medical oversight for these potent medications.
5 min read
Why Indians Should Use Ozempic Cautiously: Understanding the Reason
With the introduction of new weight-loss and diabetes drugs like Ozempic in India, endocrinologists are emphasizing the need for cautious and medically supervised use. Concerns arise particularly for individuals with a 'thin-fat' phenotype, who may experience adverse effects.
3 min read
Scientists Experiment with GLP-1 Drugs for Overweight Canines and Felines
A biopharmaceutical firm is planning a pilot study using GLP-1 agonists on obese cats, similar to drugs like Ozempic and Wegovy used for human weight loss. The treatment involves microchip implants that release the drug over six months. Similar trials are planned for dogs.
2 min read
Are Sexual Adverse Reactions Emerging With GLP-1 Receptor Agonists?
GLP-1 agonists, initially for blood sugar and weight loss, are now investigated for their impact on sexual function. Studies reveal diverse effects on libido, influenced by various factors. Some experience increased libido, while others report a decline.
4 min read
Reduced Gestational Diabetes Risk Observed with GLP-1 Use Before Pregnancy
A retrospective cohort study revealed that women taking GLP-1 receptor agonists before pregnancy exhibited a lower incidence of gestational diabetes. However, the study also indicated a potentially higher risk of pre-eclampsia in this group. These findings warrant further investigation due to the small sample size and potential confounding factors.
4 min read
Setmelanotide Potentially Enhances Obesity Drug Response in Hypothalamic Obesity
A recent study presented at ObesityWeek suggests that setmelanotide, when used alongside GLP-1 therapy, may lead to a substantial reduction in BMI for individuals with acquired hypothalamic obesity. The research indicates that restoring melanocortin-4 receptor pathway signaling could improve response to other anti-obesity treatments.
2 min read